Stay Tuned: ASCO 2010 is Just Around the Corner

Article

The theme of this year’s ASCO meeting is “advancing quality through innovation.” As always, the vast scope of this annual meeting is daunting. In order to give our readers an ongoing analysis of ASCO ’10, The Oncology Forum will be posting daily from Chicago, parsing out the best sessions and most relevant clinical information.

The theme of this year’s annual  ASCO meeting is “advancing quality through innovation.” As always, the vast scope of this international meeting is daunting. In order to give our readers an ongoing analysis of ASCO ’10, The Oncology Forum will be posting daily from Chicago, parsing out the best sessions and most relevant clinical information. 

The Forum will also highlight the most important practice management information, nuts & bolts tips that will help your practice’s bottom line and analysis of how Obama’s healthcare bill will impact the ability to treat your patients in the brave new world of comparative effectiveness research (CER) and steep Medicare cuts.


Here’s a new feature from this year’s meeting:

Trials in Progress Poster Session
 

The new Trials in Progress Poster Session will facilitate awareness of and dialogue about open, ongoing clinical trials. It differs from other Poster Sessions in that:

--outcomes data or results are not included,

--the goal is to promote discussion among trial investigators, to encourage recruitment of new investigators or sites, and to stimulate discussion of successor or confirmatory trials, 

--the focus is on the background of the science behind the trial, and preclinical or earlier-phase data (preferably with references) is encouraged.
 

Also, watch The Forum for exclusive interviews from the meeting's top presenters.

Recent Videos
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content